Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    David I Quinn, MD

    TitleAssociate Professor of Medicine (Clinical Scholar)
    SchoolKeck School of Medicine of USC
    DepartmentMedicine
    AddressNOR 3453
    Health Sciences Campus
    Los Angeles California 90089-9173
    Phone+1 323 865 3956
    vCardDownload vCard
      Other Positions
      TitleSection Head, Genitourinary (Gu) Oncology, Division of Cancer Medicine and Blood Diseases in The Department of Medicine


      Collapse Overview 
      Collapse Overview
      David Ian Quinn MBBS Honors Class I, PhD, FRACP FACP is an international expert in the field of clinical trials and molecular correlative studies in genitourinary cancer. Dr. Quinn is the medical director of the Norris Cancer Hospital and Clinics, head of the Section of Genitourinary Medical Oncology and associate professor of Medicine in the Division of Cancer Medicine and Blood Diseases at the Keck School of Medicine of USC. Prior experience includes Directorship of the Clinical Investigation Support Office and Leadership of the Genitourinary Cancer and Developmental Therapeutics Programs for the USC Norris Comprehensive Cancer Center.

      He is a medical oncologist with focus in the field of clinical trials and molecular correlative studies in genitourinary cancer and early therapeutics. David Quinn has published more than 200 papers, reviews and chapters including recent publications in the journals Cancer Research, Clinical Cancer Research, Oncogene, Proceedings of the National Academy of Science, Journal of the National Cancer Institute, Lancet, Lancet Oncology, New England Journal of Medicine and Journal of Clinical Oncology. Dr. Quinn is a reviewer for more than 50 peer-reviewed journals and is on the editorial boards of is on the editorial boards of American Journal of Clinical Oncology, cancer.net (American Society of Clinical Oncology), Clinical Genitourinary Cancer, Bladder Cancer and Annals of Oncology. Dr. Quinn is a member of the NCI Prostate Cancer Task Force, Co-Chair for Genitourinary Cancer in the California Cancer Consortium and is SWOG organ site chair for advanced prostate cancer. He is a full member of the Department of Defense Integration Panel for Prostate Cancer Awards and has been an invited speaker in more than 40 countries.

      Dr. Quinn's current focus is on clinical trials and translation applications at USC and with SWOG and the California Cancer Consortium, where he has been principal investigator on more than 100 clinical trials for locally advanced and castrate-resistant prostate cancer, high grade urothelial cancer, advanced renal cell cancer, refractory germ cell tumors and adrenocortical carcinoma.


      Collapse Biography 
      Collapse Clinical Trials
      Collapse Awards and Honors
      University of New South Wales1987Gordon Lowe Memorial Prize
      University of New South Wales1987Honours First Class Bachelor of Medicine, Bachelor of Surgery
      National Health and Medical Research Council of Australia1996  - 1999Postgraduate Medical Scholarship
      Postgraduate Medical Council of New South Wales2000Distinguished Contribution Award
      St. Vincent's Clinic Foundation2000The David Wilson Travelling Fellowship
      National Health and Medical Research Council of Australia2000  - 2003Neil Hamilton Fairley Fellowship
      Royal Australasian College of Physicians2001Vincent Fairfax Family Fellowship
      USC Norris Cancer Center and Hospital2002The Spirit of Norris Award
      Castle Connolly Medical2010America's Top Doctors

      Collapse ORNG Applications 
      Collapse Websites

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Barzi A, Klein EA, Daneshmand S, Gill I, Quinn D, Sadeghi S. Access to high-volume surgeons and the opportunity cost of performing radical prostatectomy by low-volume providers. Urol Oncol. 2017 Mar 08. PMID: 28284890.
        View in: PubMed
      2. Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn D, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017 Feb 17. PMID: 28212060.
        View in: PubMed
      3. Barzi A, Lenz HJ, Quinn D, Sadeghi S. Comparative effectiveness of screening strategies for colorectal cancer. Cancer. 2017 Jan 24. PMID: 28117881.
        View in: PubMed
      4. Sarantopoulos J, Mita AC, He A, Wade JL, Hsueh CT, Morris JC, Lockhart AC, Quinn D, Hwang J, Mier J, Zhang W, Wack C, Yin J, Clot PF, Rixe O. Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study. Cancer Chemother Pharmacol. 2017 Jan 05. PMID: 28058445.
        View in: PubMed
      5. Abreu A, Fay C, Park D, Quinn D, Dorff T, Carpten J, Kuhn P, Gill P, Almeida F, Gill I. Robotic salvage retroperitoneal and pelvic lymph node dissection for 'node-only' recurrent prostate cancer: technique and initial series. BJU Int. 2016 Dec 15. PMID: 27981731.
        View in: PubMed
      6. Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn D, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2016 Dec 07. PMID: 27939400.
        View in: PubMed
      7. Rini BI, McDermott DF, Hammers H, Bro W, Bukowski RM, Faba B, Faba J, Figlin RA, Hutson T, Jonasch E, Joseph RW, Leibovich BC, Olencki T, Pantuck AJ, Quinn D, Seery V, Voss MH, Wood CG, Wood LS, Atkins MB. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. J Immunother Cancer. 2016; 4:81. PMID: 27891227.
        View in: PubMed
      8. Ballas LK, de Castro Abreu AL, Quinn D. What Medical, Urologic, and Radiation Oncologists Want from Molecular Imaging of Prostate Cancer. J Nucl Med. 2016 Oct; 57(Suppl 3):6S-12S. PMID: 27694176.
        View in: PubMed
      9. Yu SS, Quinn D, Dorff TB. Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection. Onco Targets Ther. 2016; 9:5825-5837. PMID: 27713636.
        View in: PubMed
      10. Penson DF, Lin DW, Karsh L, Quinn D, Shevrin DH, Shore N, Symanowski JT, Brown B, Forer D, Wong EK, Flanders SC. Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research. Future Oncol. 2016 Dec; 12(23):2689-2699. PMID: 27528114.
        View in: PubMed
      11. Dorff TB, Groshen S, Garcia A, Shah M, Tsao-Wei D, Pham H, Cheng CW, Brandhorst S, Cohen P, Wei M, Longo V, Quinn D. Safety and feasibility of fasting in combination with platinum-based chemotherapy. BMC Cancer. 2016; 16(1):360. PMID: 27282289.
        View in: PubMed
      12. Hollar TL, Cook N, Quinn D, Phillips T, DeLucca M. Smoke-Free Multi-unit Housing Policies Show Promise in Reducing Secondhand Smoke Exposure Among Racially and Ethnically Diverse, Low-Income Seniors. J Immigr Minor Health. 2016 May 17. PMID: 27189486.
        View in: PubMed
      13. Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, Tangen CM, Rosenthal M, Petrylak DP, Hussain M, Vogelzang NJ, Thompson IM, Chi KN, de Bono J, Armstrong AJ, Eisenberger MA, Fandi A, Li S, Araujo JC, Logothetis CJ, Quinn D, Morris MJ, Higano CS, Tannock IF, Small EJ. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. J Clin Oncol. 2016 May 10; 34(14):1652-9. PMID: 26951312.
        View in: PubMed
      14. Petrylak DP, Tagawa ST, Kohli M, Eisen A, Canil C, Sridhar SS, Spira A, Yu EY, Burke JM, Shaffer D, Pan CX, Kim JJ, Aragon-Ching JB, Quinn D, Vogelzang NJ, Tang S, Zhang H, Cavanaugh CT, Gao L, Kauh JS, Walgren RA, Chi KN. Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. J Clin Oncol. 2016 May 1; 34(13):1500-9. PMID: 26926681.
        View in: PubMed
      15. Dorff TB, Schuckman AK, Schwartz R, Rashad S, Bulbul A, Cai J, Pinski J, Ma Y, Danenberg K, Skinner E, Quinn D. Epidermal Growth Factor Receptor, Excision-Repair Cross-Complementation Group 1 Protein, and Thymidylate Synthase Expression in Penile Cancer. Clin Genitourin Cancer. 2016 Oct; 14(5):450-456.e1. PMID: 26935231.
        View in: PubMed
      16. Wu Y, Chen YX, Yan J, Quinn D, Dong P, Sawyer SW, Soman P. Fabrication of conductive gelatin methacrylate-polyaniline hydrogels. Acta Biomater. 2016 Mar 15; 33:122-30. PMID: 26821341.
        View in: PubMed
      17. Hu BR, Fairey AS, Madhav A, Yang D, Li M, Groshen S, Stephens C, Kim PH, Virk N, Wang L, Martin SE, Erho N, Davicioni E, Jenkins RB, Den RB, Xu T, Xu Y, Gill IS, Quinn D, Goldkorn A. AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth. Prostate. 2016 May; 76(6):597-608. PMID: 26771938.
        View in: PubMed
      18. Barzi A, Klein EA, Dorff TB, Quinn D, Sadeghi S. Prostatectomy at high-volume centers improves outcomes and lowers the costs of care for prostate cancer. Prostate Cancer Prostatic Dis. 2016 Mar; 19(1):84-91. PMID: 26666409.
        View in: PubMed
      19. Quinn D, Lara PN. Renal-Cell Cancer--Targeting an Immune Checkpoint or Multiple Kinases. N Engl J Med. 2015 Nov 5; 373(19):1872-4. PMID: 26406149.
        View in: PubMed
      20. Kramar A, Negrier S, Sylvester R, Joniau S, Mulders P, Powles T, Bex A, Bonnetain F, Bossi A, Bracarda S, Bukowski R, Catto J, Choueiri TK, Crabb S, Eisen T, El Demery M, Fitzpatrick J, Flamand V, Goebell PJ, Gravis G, Houédé N, Jacqmin D, Kaplan R, Malavaud B, Massard C, Melichar B, Mourey L, Nathan P, Pasquier D, Porta C, Pouessel D, Quinn D, Ravaud A, Rolland F, Schmidinger M, Tombal B, Tosi D, Vauleon E, Volpe A, Wolter P, Escudier B, Filleron T. Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†. Ann Oncol. 2015 Dec; 26(12):2392-8. PMID: 26371288.
        View in: PubMed
      21. Morgan RJ, Synold TW, Longmate JA, Quinn D, Gandara D, Lenz HJ, Ruel C, Xi B, Lewis MD, Colevas AD, Doroshow J, Newman EM. Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial. Cancer Chemother Pharmacol. 2015 Nov; 76(5):897-907. PMID: 26362045.
        View in: PubMed
      22. Quinn D, Frith D. Assessing the damage control resuscitation: Development, drivers and direction. Emerg Med Australas. 2015 Oct; 27(5):485-7. PMID: 26315261.
        View in: PubMed
      23. Yu H, Liu R, Ma B, Li X, Yen HY, Zhou Y, Krasnoperov V, Xia Z, Zhang X, Bove AM, Buscarini M, Parekh D, Gill IS, Liao Q, Tretiakova M, Quinn D, Zhao J, Gill PS. Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma. Br J Cancer. 2015 Aug 11; 113(4):616-25. PMID: 26180925.
        View in: PubMed
      24. Dorff TB, Hu J, Quinn D. Relapsed and refractory germ cell tumors: Finessing the rough end of a beautiful story. Urol Oncol. 2015 Aug; 33(8):341-2. PMID: 26094170.
        View in: PubMed
      25. Yu EY, Li H, Higano CS, Agarwal N, Pal SK, Alva A, Heath EI, Lam ET, Gupta S, Lilly MB, Inoue Y, Chi KN, Vogelzang NJ, Quinn D, Cheng HH, Plymate SR, Hussain M, Tangen CM, Thompson IM. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2015 May 10; 33(14):1601-8. PMID: 25847934.
        View in: PubMed
      26. Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn D, Hesseltine E, Ronchi CL, Terzolo M, Choueiri TK, Poondru S, Fleege T, Rorig R, Chen J, Stephens AW, Worden F, Hammer GD. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015 Apr; 16(4):426-35. PMID: 25795408.
        View in: PubMed
      27. Jadvar H, Challa S, Quinn D, Conti PS. One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer. Cancer Biother Radiopharm. 2015 Jun; 30(5):195-9. PMID: 25746633.
        View in: PubMed
      28. Satkunasivam R, Kim AE, Desai M, Nguyen MM, Quinn D, Ballas L, Lewinger JP, Stern MC, Hamilton AS, Aron M, Gill IS. Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis. J Urol. 2015 Aug; 194(2):378-85. PMID: 25711194.
        View in: PubMed
      29. Jadvar H, Groshen SG, Quinn D. Association of overall survival with glycolytic activity of castrate-resistant prostate cancer metastases. Radiology. 2015 Feb; 274(2):624-5. PMID: 25625748.
        View in: PubMed
      30. Quinn D, Shore ND, Egawa S, Gerritsen WR, Fizazi K. Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms. Urol Oncol. 2015 May; 33(5):245-60. PMID: 25575714.
        View in: PubMed
      31. Vashistha V, Quinn D, Dorff TB, Daneshmand S. Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review. BMC Cancer. 2014; 14:966. PMID: 25515347.
        View in: PubMed
      32. Ballas LK, Hu BR, Quinn D. Chromoplexy and hypoxic microenvironment drives prostate cancer. Lancet Oncol. 2014 Dec; 15(13):1419-21. PMID: 25456359.
        View in: PubMed
      33. Piatek CI, Raja GL, Ji L, Gitlitz BJ, Dorff TB, Quinn D, Hu J, El-Khoueiry AB, Pham HQ, Roman L, Garcia AA. Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors. Cancer Chemother Pharmacol. 2014 Dec; 74(6):1227-34. PMID: 25374407.
        View in: PubMed
      34. Milowsky MI, Dittrich C, Durán I, Jagdev S, Millard FE, Sweeney CJ, Bajorin D, Cerbone L, Quinn D, Stadler WM, Rosenberg JE, Lochheed M, Sen P, Squires M, Shi M, Sternberg CN. Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. Eur J Cancer. 2014 Dec; 50(18):3145-52. PMID: 25457633.
        View in: PubMed
      35. Goldkorn A, Ely B, Tangen CM, Tai YC, Xu T, Li H, Twardowski P, Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Garzotto M, Mack PC, Lara P, Higano CS, Hussain M, Vogelzang NJ, Thompson IM, Cote RJ, Quinn D. Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: A phase III metastatic castration resistant prostate cancer trial. Int J Cancer. 2015 Apr 15; 136(8):1856-62. PMID: 25219358.
        View in: PubMed
      36. Liu SV, Tsao-Wei DD, Xiong S, Groshen S, Dorff TB, Quinn D, Tai YC, Engel J, Hawes D, Schally AV, Pinski JK. Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer. Clin Cancer Res. 2014 Dec 15; 20(24):6277-83. PMID: 25278449.
        View in: PubMed
      37. Dorff TB, Groshen S, Tsao-Wei DD, Xiong S, Gross ME, Vogelzang N, Quinn D, Pinski JK. A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2014 Dec; 17(4):359-65. PMID: 25245366.
        View in: PubMed
      38. Alpert BS, Quinn D, Gallick D. Oscillometric blood pressure: a review for clinicians. J Am Soc Hypertens. 2014 Dec; 8(12):930-8. PMID: 25492837.
        View in: PubMed
      39. Li X, Choi WW, Yan R, Yu H, Krasnoperov V, Kumar SR, Schuckman A, Klumpp DJ, Pan CX, Quinn D, Gill IS, Gill PS, Liu R. The Differential Expression of EphB2 and EphB4 Receptor Kinases in Normal Bladder and in Transitional Cell Carcinoma of the Bladder. PLoS One. 2014; 9(8):e105326. PMID: 25148033.
        View in: PubMed
      40. Quinn D. Carboplatin's fourth decade: still searching for its sweet spot. Ann Oncol. 2014 Aug; 25(8):1457-8. PMID: 24950978.
        View in: PubMed
      41. Cheng CW, Adams GB, Perin L, Wei M, Zhou X, Lam BS, Da Sacco S, Mirisola M, Quinn D, Dorff TB, Kopchick JJ, Longo VD. Prolonged Fasting Reduces IGF-1/PKA to Promote Hematopoietic-Stem-Cell-Based Regeneration and Reverse Immunosuppression. Cell Stem Cell. 2014 Jun 5; 14(6):810-23. PMID: 24905167.
        View in: PubMed
      42. Dorff TB, Hu JS, Quinn D. Salvage chemotherapy for refractory germ cell tumors. Oncology (Williston Park). 2014 Jun; 28(6):498-500. PMID: 25134324.
        View in: PubMed
      43. Apolo AB, Kim JW, Bochner BH, Steinberg SM, Bajorin DF, Kevin Kelly W, Agarwal PK, Koppie TM, Kaag MG, Quinn D, Vogelzang NJ, Sridhar SS. Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States. Urol Oncol. 2014 Jul; 32(5):637-44. PMID: 24840869.
        View in: PubMed
      44. Hussain M, Daignault S, Agarwal N, Grivas PD, Siefker-Radtke AO, Puzanov I, MacVicar GR, Levine EG, Srinivas S, Twardowski P, Eisenberger MA, Quinn D, Vaishampayan UN, Yu EY, Dawsey S, Day KC, Day ML, Al-Hawary M, Smith DC. A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer. 2014 Sep 1; 120(17):2684-93. PMID: 24802654.
        View in: PubMed
      45. Quinn D. Skate park injury: A new mechanism of sternoclavicular joint dislocation. Emerg Med Australas. 2014 Jun; 26(3):316-7. PMID: 24712682.
        View in: PubMed
      46. Dart RA, Alpert B, Quinn D. Effect of mechanical behavior of the brachial artery on blood pressure measurement during cuff inflation and cuff deflation. Blood Press Monit. 2014 Apr; 19(2):120. PMID: 24618886.
        View in: PubMed
      47. Goldkorn A, Ely B, Quinn D, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Datar RH, Garzotto M, Mack PC, Lara P, Higano CS, Hussain M, Thompson IM, Cote RJ, Vogelzang NJ. Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2014 Apr 10; 32(11):1136-42. PMID: 24616308.
        View in: PubMed
      48. Rini BI, Quinn D, Baum M, Wood LS, Tarazi J, Rosbrook B, Arruda LS, Cisar L, Roberts WG, Kim S, Motzer RJ. Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial. Target Oncol. 2015 Mar; 10(1):45-53. PMID: 24595903.
        View in: PubMed
      49. Lara PN, Ely B, Quinn D, Mack PC, Tangen C, Gertz E, Twardowski PW, Goldkorn A, Hussain M, Vogelzang NJ, Thompson IM, Van Loan MD. Serum Biomarkers of Bone Metabolism in Castration-Resistant Prostate Cancer Patients With Skeletal Metastases: Results From SWOG 0421. J Natl Cancer Inst. 2014 Apr 1; 106(4):dju013. PMID: 24565955.
        View in: PubMed
      50. Bhatia S, Curti B, Ernstoff MS, Gordon M, Heath EI, Miller WH, Puzanov I, Quinn D, Flaig TW, VanVeldhuizen P, Byrnes-Blake K, Freeman JA, Bittner R, Hunder N, Souza S, Thompson JA. Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. J Immunother Cancer. 2014; 2:2. PMID: 24829759.
        View in: PubMed
      51. Quinn D, Vaishampayan U, Higano CS, Lin DW, Shore ND, Beer TM. Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T. Expert Rev Anticancer Ther. 2014 Jan; 14(1):51-61. PMID: 24224900.
        View in: PubMed
      52. Dorff TB, Pal SK, Quinn D. Novel tyrosine kinase inhibitors for renal cell carcinoma. Expert Rev Clin Pharmacol. 2014 Jan; 7(1):67-73. PMID: 24308791.
        View in: PubMed
      53. Jadvar H, Quinn D. Targeted a-Particle Therapy of Bone Metastases in Prostate Cancer. Clin Nucl Med. 2013 Dec; 38(12):966-71. PMID: 24212441.
        View in: PubMed
      54. Dorff TB, Wilkins C, Hepgur M, Quinn D. Durable complete remission from castration-resistant prostate cancer with sipuleucel-T after estrogen withdrawal. Clin Genitourin Cancer. 2014 Apr; 12(2):e55-8. PMID: 24331572.
        View in: PubMed
      55. Mitra AP, Skinner EC, Schuckman AK, Quinn D, Dorff TB, Daneshmand S. Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: A critical analysis of 1,994 patients. Urol Oncol. 2014 Jan; 32(1):52.e1-9. PMID: 24239476.
        View in: PubMed
      56. Brown A, Ma Y, Danenberg K, Schuckman AK, Pinski JK, Pagliaro LC, Quinn D, Dorff TB. Epidermal Growth Factor Receptor-targeted Therapy in Squamous Cell Carcinoma of the Penis: A Report of 3 Cases. Urology. 2014 Jan; 83(1):159-66. PMID: 24238569.
        View in: PubMed
      57. Dorff TB, Tsao-Wei DD, Groshen S, Boswell W, Goldkorn A, Xiong S, Quinn D, Pinski JK. Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2013 Dec; 11(4):416-22. PMID: 24099865.
        View in: PubMed
      58. Quinn D, Tangen CM, Hussain M, Lara PN, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol. 2013 Aug; 14(9):893-900. PMID: 23871417.
        View in: PubMed
      59. Goldkorn A, Aparicio AM, Quinn D. Therapeutic windows and opportunity cost cast upon prostate cancer's fatal shore. Ann Oncol. 2013 Jul; 24(7):1717-20. PMID: 23798673.
        View in: PubMed
      60. Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Pinski JK, Quinn D. Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. J Nucl Med. 2013 Aug; 54(8):1195-201. PMID: 23785174.
        View in: PubMed
      61. Hepgur M, Sadeghi S, Dorff TB, Quinn D. Tivozanib in the treatment of renal cell carcinoma. Biologics. 2013; 7:139-48. PMID: 23788831.
        View in: PubMed
      62. Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn D, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013 Apr 4; 368(14):1314-25. PMID: 23550669.
        View in: PubMed
      63. Pal SK, Quinn D. Differentiating mTOR inhibitors in renal cell carcinoma. Cancer Treat Rev. 2013 Nov; 39(7):709-19. PMID: 23433636.
        View in: PubMed
      64. Feldman DR, Einhorn LH, Quinn D, Loriot Y, Joffe JK, Vaughn DJ, Fléchon A, Hajdenberg J, Halim AB, Zahir H, Motzer RJ. A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors. Invest New Drugs. 2013 Aug; 31(4):1016-22. PMID: 23417696.
        View in: PubMed
      65. Dorff TB, Quinn D. Speeding dating for docetaxel and recent debutantes in castration-resistant prostate cancer: 'plus or minus' may be a minus. Ann Oncol. 2013 Feb; 24(2):270-2. PMID: 23341479.
        View in: PubMed
      66. Roth BJ, Krilov L, Adams S, Aghajanian CA, Bach P, Braiteh F, Brose MS, Ellis LM, Erba H, George DJ, Gilbert MR, Jacobson JO, Larsen EC, Lichtman SM, Partridge AH, Patel JD, Quinn D, Robison LL, von Roenn JH, Samlowski W, Schwartz GK, Vogelzang NJ. Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol. 2013 Jan 1; 31(1):131-61. PMID: 23213095.
        View in: PubMed
      67. Fairey AS, Daneshmand S, Quinn D, Dorff T, Dorin R, Lieskovsky G, Schuckman A, Cai J, Miranda G, Skinner EC. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: A retrospective analysis from the University of Southern California. Urol Oncol. 2013 Nov; 31(8):1737-43. PMID: 23141776.
        View in: PubMed
      68. Fahed E, Hansel DE, Raghavan D, Quinn D, Dorff TB. Small cell bladder cancer: biology and management. Semin Oncol. 2012 Oct; 39(5):615-8. PMID: 23040258.
        View in: PubMed
      69. Eisen T, Joensuu H, Nathan PD, Harper PG, Wojtukiewicz MZ, Nicholson S, Bahl A, Tomczak P, Pyrhonen S, Fife K, Bono P, Boxall J, Wagner A, Jeffers M, Lin T, Quinn D. Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet Oncol. 2012 Oct; 13(10):1055-62. PMID: 22959186.
        View in: PubMed
      70. Sternberg CN, Bellmunt J, Sonpavde G, Siefker-Radtke AO, Stadler WM, Bajorin DF, Dreicer R, George DJ, Milowsky MI, Theodorescu D, Vaughn DJ, Galsky MD, Soloway MS, Quinn D. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol. 2013 Jan; 63(1):58-66. PMID: 22917984.
        View in: PubMed
      71. Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Gross ME, Pinski JK, Quinn D. Prospective Evaluation of 18F-NaF and 18F-FDG PET/CT in Detection of Occult Metastatic Disease in Biochemical Recurrence of Prostate Cancer. Clin Nucl Med. 2012 Jul; 37(7):637-43. PMID: 22691503.
        View in: PubMed
      72. Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Jänne PA, Quinn D, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato SG, Vogelzang NJ, Chen HX, Stadler WM, Vokes EE. Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine/Cisplatin Plus Bevacizumab or Placebo in Patients With Malignant Mesothelioma. J Clin Oncol. 2012 Jul 10; 30(20):2509-15. PMID: 22665541.
        View in: PubMed
      73. Thara E, Dorff TB, Averia-Suboc M, Luther M, Reed ME, Pinski JK, Quinn D. Immune response to sipuleucel-T in prostate cancer. Cancers (Basel). 2012; 4(2):420-41. PMID: 24213318.
        View in: PubMed
      74. Zhang SY, Thara E, Quinn D, Dorff T. Blood cells and their use in active immunotherapy of prostate cancer. Hum Vaccin Immunother. 2012 Apr 1; 8(4):528-33. PMID: 22370509.
        View in: PubMed
      75. Pal SK, Williams S, Josephson DY, Carmichael C, Vogelzang NJ, Quinn D. Novel Therapies for Metastatic Renal Cell Carcinoma: Efforts to Expand beyond the VEGF/mTOR Signaling Paradigm. Mol Cancer Ther. 2012 Mar; 11(3):526-37. PMID: 22351744.
        View in: PubMed
      76. Choueiri TK, Ross RW, Jacobus S, Vaishampayan U, Yu EY, Quinn D, Hahn NM, Hutson TE, Sonpavde G, Morrissey SC, Buckle GC, Kim WY, Petrylak DP, Ryan CW, Eisenberger MA, Mortazavi A, Bubley GJ, Taplin ME, Rosenberg JE, Kantoff PW. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol. 2012 Feb 10; 30(5):507-12. PMID: 22184381.
        View in: PubMed
      77. Armstrong AJ, Ferrari AC, Quinn D. The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancer. Clin Adv Hematol Oncol. 2011 Dec; 9(12 Suppl 28):1-14; quiz 15-6. PMID: 22407145.
        View in: PubMed
      78. Desai B, Elatre W, Quinn D, Jadvar H. FDG PET/CT demonstration of pancreatic metastasis from prostate cancer. Clin Nucl Med. 2011 Oct; 36(10):961-2. PMID: 21892064.
        View in: PubMed
      79. Tolcher AW, Quinn D, Ferrari A, Ahmann F, Giaccone G, Drake T, Keating A, de Bono JS. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann Oncol. 2012 Apr; 23(4):968-73. PMID: 21859898.
        View in: PubMed
      80. Mitra AP, Quinn D, Dorff TB, Skinner EC, Schuckman AK, Miranda G, Gill IS, Daneshmand S. Factors influencing post-recurrence survival in bladder cancer following radical cystectomy. BJU Int. 2012 Mar; 109(6):846-54. PMID: 21812902.
        View in: PubMed
      81. Thara E, Dorff TB, Pinski JK, Quinn D. Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer. Maturitas. 2011 Aug; 69(4):296-303. PMID: 21621934.
        View in: PubMed
      82. Swanson GP, Quinn D. Using molecular markers to help predict who will fail after radical prostatectomy. Prostate Cancer. 2011; 2011:290160. PMID: 22096655.
        View in: PubMed
      83. Shek D, Longmate J, Quinn D, Margolin KA, Twardowski P, Gandara DR, Frankel P, Pan CX, Lara PN. A phase II trial of gefitinib and pegylated IFNa in previously treated renal cell carcinoma. Int J Clin Oncol. 2011 Oct; 16(5):494-9. PMID: 21431345.
        View in: PubMed
      84. Quinn D, Gross M. Show us a sign: the search for "game changing" prostate cancer biomarkers. Lancet Oncol. 2011 Mar; 12(3):204-6. PMID: 21310657.
        View in: PubMed
      85. Iqbal S, Tsao-Wei DD, Quinn D, Gitlitz BJ, Groshen S, Aparicio A, Lenz HJ, El-Khoueiry A, Pinski J, Garcia AA. Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors. Am J Clin Oncol. 2011 Feb; 34(1):27-31. PMID: 20142723.
        View in: PubMed
      86. Ell K, Xie B, Kapetanovic S, Quinn D, Lee PJ, Wells A, Chou CP. One-year follow-up of collaborative depression care for low-income, predominantly Hispanic patients with cancer. Psychiatr Serv. 2011 Feb; 62(2):162-70. PMID: 21285094.
        View in: PubMed
      87. Dorff TB, Quinn D. Cabazitaxel in prostate cancer: stretching a string. Lancet. 2010 Oct 2; 376(9747):1119-20. PMID: 20888974.
        View in: PubMed
      88. Twardowski P, Stadler WM, Frankel P, Lara PN, Ruel C, Chatta G, Heath E, Quinn D, Gandara DR. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology. 2010 Oct; 76(4):923-6. PMID: 20646741.
        View in: PubMed
      89. Bellmunt J, Fishman M, Eisen T, Quinn D. Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients. Expert Rev Anticancer Ther. 2010 Jun; 10(6):825-35. PMID: 20553208.
        View in: PubMed
      90. Dorff TB, Goldman B, Pinski JK, Mack PC, Lara PN, Van Veldhuizen PJ, Quinn D, Vogelzang NJ, Thompson IM, Hussain MH. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res. 2010 Jun 1; 16(11):3028-34. PMID: 20484019.
        View in: PubMed
      91. Bellmunt J, Eisen T, Fishman M, Quinn D. Experience with sorafenib and adverse event management. Crit Rev Oncol Hematol. 2011 Apr; 78(1):24-32. PMID: 20399677.
        View in: PubMed
      92. Safdie FM, Dorff T, Quinn D, Fontana L, Wei M, Lee C, Cohen P, Longo VD. Fasting and cancer treatment in humans: A case series report. Aging (Albany NY). 2009 Dec; 1(12):988-1007. PMID: 20157582.
        View in: PubMed
      93. Dorff TB, Quinn D. Perioperative chemotherapy for urothelial cancer: how have we made a "sow's ear" out of a chemotherapy-sensitive tumor? Cancer. 2009 Nov 15; 115(22):5139-42. PMID: 19645028.
        View in: PubMed
      94. Gordon MS, Hussey M, Nagle RB, Lara PN, Mack PC, Dutcher J, Samlowski W, Clark JI, Quinn D, Pan CX, Crawford D. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol. 2009 Dec 1; 27(34):5788-93. PMID: 19884559.
        View in: PubMed
      95. Dorff TB, Goldkorn A, Quinn D. Targeted therapy in renal cancer. Ther Adv Med Oncol. 2009 Nov; 1(3):183-205. PMID: 21789121.
        View in: PubMed
      96. Lara PN, Longmate J, Evans CP, Quinn D, Twardowski P, Chatta G, Posadas E, Stadler W, Gandara DR. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs. 2009 Mar; 20(3):179-84. PMID: 19396016.
        View in: PubMed
      97. Teo SS, Alfaham M, Evans MR, Watson JM, Riordan A, Sonnenberg P, Clark J, Hayward A, Sharland M, Moore-Gillon J, Novelli V, Quinn D, Shingadia D. An evaluation of the completeness of reporting of childhood tuberculosis. Eur Respir J. 2009 Jul; 34(1):176-9. PMID: 19251788.
        View in: PubMed
      98. Quinn D, Nemunaitis J, Fuloria J, Britten CD, Gabrail N, Yee L, Acharya M, Chan K, Cohen N, Dudov A. Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. Clin Pharmacokinet. 2009; 48(3):199-209. PMID: 19385713.
        View in: PubMed
      99. Cheung E, Pinski J, Dorff T, Groshen S, Quinn D, Reynolds CP, Maurer BJ, Lara PN, Tsao-Wei DD, Twardowski P, Chatta G, McNamara M, Gandara DR. Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial. Clin Genitourin Cancer. 2009 Jan; 7(1):43-50. PMID: 19213668.
        View in: PubMed
      100. Dorff TB, Tangen CM, Crawford ED, Petrylak DP, Higano CS, Raghavan D, Quinn D, Vogelzang NJ, Thompson IM, Hussain MH. COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCER. Ther Adv Med Oncol. 2009; 1(2):69-77. PMID: 21085622.
        View in: PubMed
      101. Dorff TB, Tsao-Wei D, Miranda G, Skinner DG, Stein JP, Quinn D. Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience. World J Urol. 2009 Feb; 27(1):39-44. PMID: 19020886.
        View in: PubMed
      102. Smith DC, Mackler NJ, Dunn RL, Hussain M, Wood D, Lee CT, Sanda M, Vaishampayan U, Petrylak DP, Quinn D, Beekman K, Montie JE. Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder. J Urol. 2008 Dec; 180(6):2384-8; discussion 2388. PMID: 18930256.
        View in: PubMed
      103. Ell K, Xie B, Quon B, Quinn D, Dwight-Johnson M, Lee PJ. Randomized controlled trial of collaborative care management of depression among low-income patients with cancer. J Clin Oncol. 2008 Sep 20; 26(27):4488-96. PMID: 18802161.
        View in: PubMed
      104. Chan JS, Beer TM, Quinn D, Pinski JK, Garzotto M, Sokoloff M, Dehaze DR, Ryan CW. A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer. BJU Int. 2008 Dec; 102(11):1601-6. PMID: 18782306.
        View in: PubMed
      105. Tagawa ST, Dorff TB, Rochanda L, Ye W, Boyle S, Raghavan D, Lieskovsky G, Skinner DG, Quinn D, Liebman HA. Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic prostatectomy. BJU Int. 2008 Nov; 102(9):1086-91. PMID: 18671791.
        View in: PubMed
      106. O'Brien PM, Davies MJ, Scurry JP, Smith AN, Barton CA, Henderson MJ, Saunders DN, Gloss BS, Patterson KI, Clancy JL, Heinzelmann-Schwarz VA, Murali R, Scolyer RA, Zeng Y, Williams ED, Scurr L, Defazio A, Quinn D, Watts CK, Hacker NF, Henshall SM, Sutherland RL. The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro. Br J Cancer. 2008 Mar 25; 98(6):1085-93. PMID: 18349819.
        View in: PubMed
      107. Chee KG, Longmate J, Quinn D, Chatta G, Pinski J, Twardowski P, Pan CX, Cambio A, Evans CP, Gandara DR, Lara PN. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer. 2007 Dec; 5(7):433-7. PMID: 18272025.
        View in: PubMed
      108. Stadler WM, Desai AA, Quinn D, Bukowski R, Poiesz B, Kardinal CG, Lewis N, Makalinao A, Murray P, Torti FM. A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma. Cancer Chemother Pharmacol. 2008 Apr; 61(4):689-94. PMID: 17569043.
        View in: PubMed
      109. Margolin K, Synold TW, Lara P, Frankel P, Lacey SF, Quinn D, Baratta T, Dutcher JP, Xi B, Diamond DJ, Gandara DR. Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium. J Cancer Res Clin Oncol. 2007 Oct; 133(10):705-11. PMID: 17508219.
        View in: PubMed
      110. Ell K, Quon B, Quinn D, Dwight-Johnson M, Wells A, Lee PJ, Xie B. Improving treatment of depression among low-income patients with cancer: the design of the ADAPt-C study. Gen Hosp Psychiatry. 2007 May-Jun; 29(3):223-31. PMID: 17484939.
        View in: PubMed
      111. Turner JS, Cheung EM, George J, Quinn D. Pain management, supportive and palliative care in patients with renal cell carcinoma. BJU Int. 2007 May; 99(5 Pt B):1305-12. PMID: 17441929.
        View in: PubMed
      112. Henshall SM, Horvath LG, Quinn D, Eggleton SA, Grygiel JJ, Stricker PD, Biankin AV, Kench JG, Sutherland RL. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J Natl Cancer Inst. 2006 Oct 4; 98(19):1420-4. PMID: 17018789.
        View in: PubMed
      113. Plasencia C, Martínez-Balibrea E, Martinez-Cardús A, Quinn D, Abad A, Neamati N. Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells. Int J Oncol. 2006 Jul; 29(1):225-35. PMID: 16773204.
        View in: PubMed
      114. Beer TM, Tangen CM, Nichols CR, Margolin KA, Dreicer R, Stephenson WT, Quinn D, Raghavan D, Crawford ED. Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. Cancer. 2006 Jun 15; 106(12):2624-9. PMID: 16688776.
        View in: PubMed
      115. Xia G, Kumar SR, Hawes D, Cai J, Hassanieh L, Groshen S, Zhu S, Masood R, Quinn D, Broek D, Stein JP, Gill PS. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol. 2006 Apr; 175(4):1245-52. PMID: 16515971.
        View in: PubMed
      116. Levine AM, Tulpule A, Quinn D, Gorospe G, Smith DL, Hornor L, Boswell WD, Espina BM, Groshen SG, Masood R, Gill PS. Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy. J Clin Oncol. 2006 Apr 10; 24(11):1712-9. PMID: 16520466.
        View in: PubMed
      117. Lara PN, Stadler WM, Longmate J, Quinn D, Wexler J, Van Loan M, Twardowski P, Gumerlock PH, Vogelzang NJ, Vokes EE, Lenz HJ, Doroshow JH, Gandara DR. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res. 2006 Mar 1; 12(5):1556-63. PMID: 16533781.
        View in: PubMed
      118. Xia G, Kumar SR, Stein JP, Singh J, Krasnoperov V, Zhu S, Hassanieh L, Smith DL, Buscarini M, Broek D, Quinn D, Weaver FA, Gill PS. EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival. Oncogene. 2006 Feb 2; 25(5):769-80. PMID: 16205642.
        View in: PubMed
      119. Lara PN, Koczywas M, Quinn D, Lenz HJ, Davies AM, Lau DH, Gumerlock PH, Longmate J, Doroshow JH, Schenkein D, Kashala O, Gandara DR. Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial. J Thorac Oncol. 2006 Feb; 1(2):126-34. PMID: 17409841.
        View in: PubMed
      120. Garcia AA, Iqbal S, Quinn D, Edwards S, Lenz HJ, Weber J. Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis. Invest New Drugs. 2006 Jan; 24(1):79-83. PMID: 16379039.
        View in: PubMed
      121. Hutson TE, Quinn D. Cytokine therapy: a standard of care for metastatic renal cell carcinoma? Clin Genitourin Cancer. 2005 Dec; 4(3):181-6. PMID: 16425986.
        View in: PubMed
      122. Raghavan D, Brandes LJ, Klapp K, Snyder T, Styles E, Tsao-Wei D, Lieskovsky G, Quinn D, Ramsey EW. Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases. J Urol. 2005 Nov; 174(5):1808-13; discussion 1813. PMID: 16217292.
        View in: PubMed
      123. Quek ML, Simma-Chiang V, Stein JP, Pinski J, Quinn D, Skinner DG. Postchemotherapy residual masses in advanced seminoma: current management and outcomes. Expert Rev Anticancer Ther. 2005 Oct; 5(5):869-74. PMID: 16221056.
        View in: PubMed
      124. Plasencia C, Dayam R, Wang Q, Pinski J, Burke TR, Quinn D, Neamati N. Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines. Mol Cancer Ther. 2005 Jul; 4(7):1105-13. PMID: 16020668.
        View in: PubMed
      125. Xia G, Kumar SR, Masood R, Koss M, Templeman C, Quinn D, Zhu S, Reddy R, Krasnoperov V, Gill PS. Up-regulation of EphB4 in mesothelioma and its biological significance. Clin Cancer Res. 2005 Jun 15; 11(12):4305-15. PMID: 15958611.
        View in: PubMed
      126. Xia G, Kumar SR, Masood R, Zhu S, Reddy R, Krasnoperov V, Quinn D, Henshall SM, Sutherland RL, Pinski JK, Daneshmand S, Buscarini M, Stein JP, Zhong C, Broek D, Roy-Burman P, Gill PS. EphB4 expression and biological significance in prostate cancer. Cancer Res. 2005 Jun 1; 65(11):4623-32. PMID: 15930280.
        View in: PubMed
      127. Aparicio AM, Elkhouiery AB, Quinn D. The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomy. Urol Clin North Am. 2005 May; 32(2):217-30, vii. PMID: 15862619.
        View in: PubMed
      128. Buscarini M, Quek ML, Gill P, Xia G, Quinn D, Stein JP. Molecular prognostic factors in bladder cancer. BJU Int. 2005 Apr; 95(6):739-42. PMID: 15794774.
        View in: PubMed
      129. Quinn D, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur J Cancer. 2005 Apr; 41(6):858-87. PMID: 15808955.
        View in: PubMed
      130. Lara PN, Twardowski P, Quinn D. Angiogenesis-targeted therapies in prostate cancer. Clin Prostate Cancer. 2004 Dec; 3(3):165-73. PMID: 15636683.
        View in: PubMed
      131. Newell ME, Hoy JF, Cooper SG, DeGraaff B, Grulich AE, Bryant M, Millar JL, Brew BJ, Quinn D. Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients. Cancer. 2004 Jun 15; 100(12):2627-36. PMID: 15197806.
        View in: PubMed
      132. Cagiannos I, Karakiewicz P, Graefen M, Eastham JA, Ohori M, Rabbani F, Reuter V, Wheeler T, Kupelian P, Klein E, Huland H, Hammerer PG, Erbersdobler A, Schroeder F, Wildhagen M, Quinn D, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, Morash CG, Scardino PT, Kattan MW. Is year of radical prostatectomy a predictor of outcome in prostate cancer? J Urol. 2004 Feb; 171(2 Pt 1):692-6. PMID: 14713788.
        View in: PubMed
      133. Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, Groshen S, Cote RJ, Lieskovsky G, Quinn D, Skinner DG. Microscopic and gross extravesical extension in pathological staging of bladder cancer. J Urol. 2004 Feb; 171(2 Pt 1):640-5. PMID: 14713777.
        View in: PubMed
      134. Quinn D. The future in advanced prostate cancer: take your partners or is the last dance for me? Rev Urol. 2004; 6 Suppl 10:S29-44. PMID: 16985929.
        View in: PubMed
      135. Cagiannos I, Karakiewicz P, Eastham JA, Ohori M, Rabbani F, Gerigk C, Reuter V, Graefen M, Hammerer PG, Erbersdobler A, Huland H, Kupelian P, Klein E, Quinn D, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, Morash CG, Scardino PT, Kattan MW. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol. 2003 Nov; 170(5):1798-803. PMID: 14532779.
        View in: PubMed
      136. Lara PN, Quinn D, Margolin K, Meyers FJ, Longmate J, Frankel P, Mack PC, Turrell C, Valk P, Rao J, Buckley P, Wun T, Gosselin R, Galvin I, Gumerlock PH, Lenz HJ, Doroshow JH, Gandara DR. SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res. 2003 Oct 15; 9(13):4772-81. PMID: 14581348.
        View in: PubMed
      137. Henshall SM, Afar DE, Rasiah KK, Horvath LG, Gish K, Caras I, Ramakrishnan V, Wong M, Jeffry U, Kench JG, Quinn D, Turner JJ, Delprado W, Lee CS, Golovsky D, Brenner PC, O'Neill GF, Kooner R, Stricker PD, Grygiel JJ, Mack DH, Sutherland RL. Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. Oncogene. 2003 Sep 4; 22(38):6005-12. PMID: 12955079.
        View in: PubMed
      138. Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, Groshen S, Lieskovsky G, Quinn D, Raghavan D, Skinner DG. Natural history of surgically treated bladder carcinoma with extravesical tumor extension. Cancer. 2003 Sep 1; 98(5):955-61. PMID: 12942562.
        View in: PubMed
      139. Henshall SM, Afar DE, Hiller J, Horvath LG, Quinn D, Rasiah KK, Gish K, Willhite D, Kench JG, Gardiner-Garden M, Stricker PD, Scher HI, Grygiel JJ, Agus DB, Mack DH, Sutherland RL. Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res. 2003 Jul 15; 63(14):4196-203. PMID: 12874026.
        View in: PubMed
      140. Quek ML, Quinn D, Daneshmand S, Stein JP. Molecular prognostication in bladder cancer--a current perspective. Eur J Cancer. 2003 Jul; 39(11):1501-10. PMID: 12855255.
        View in: PubMed
      141. Quinn D, Henshall SM, Brenner PC, Kooner R, Golovsky D, O'Neill GF, Turner JJ, Delprado W, Grygiel JJ, Sutherland RL, Stricker PD. Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion. Cancer. 2003 Apr 15; 97(8):1884-93. PMID: 12673714.
        View in: PubMed
      142. Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, Bauskin AR, Ward RL, Hawkins NJ, Quinn D, Russell PJ, Sutherland RL, Breit SN, Moskaluk CA, Frierson HF, Hampton GM. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A. 2003 Mar 18; 100(6):3410-5. PMID: 12624183.
        View in: PubMed
      143. Jackson P, Ow K, Yardley G, Delprado W, Quinn D, Yang JL, Russell PJ. Downregulation of KAI1 mRNA in localised prostate cancer and its bony metastases does not correlate with p53 overexpression. Prostate Cancer Prostatic Dis. 2003; 6(2):174-81. PMID: 12806379.
        View in: PubMed
      144. Graefen M, Karakiewicz PI, Cagiannos I, Quinn D, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, Klein E, Kupelian P, Skinner DG, Lieskovsky G, Bochner B, Huland H, Hammerer PG, Haese A, Erbersdobler A, Eastham JA, de Kernion J, Cangiano T, Schröder FH, Wildhagen MF, van der Kwast TH, Scardino PT, Kattan MW. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2002 Aug 1; 20(15):3206-12. PMID: 12149292.
        View in: PubMed
      145. Raghavan D, Quinn D, Skinner DG, Stein JP. Surgery and adjunctive chemotherapy for invasive bladder cancer. Surg Oncol. 2002 Jun; 11(1-2):55-63. PMID: 12031868.
        View in: PubMed
      146. Graefen M, Karakiewicz PI, Cagiannos I, Klein E, Kupelian PA, Quinn D, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, de Kernion J, Cangiano T, Schröder FH, Wildhagen MF, Scardino PT, Kattan MW. Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. J Clin Oncol. 2002 Feb 15; 20(4):951-6. PMID: 11844816.
        View in: PubMed
      147. Quinn D, Henshall SM, Haynes AM, Brenner PC, Kooner R, Golovsky D, Mathews J, O'Neill GF, Turner JJ, Delprado W, Finlayson JF, Sutherland RL, Grygiel JJ, Stricker PD. Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models. J Clin Oncol. 2001 Aug 15; 19(16):3692-705. PMID: 11504751.
        View in: PubMed
      148. Horvath LG, Henshall SM, Lee CS, Head DR, Quinn D, Makela S, Delprado W, Golovsky D, Brenner PC, O'Neill G, Kooner R, Stricker PD, Grygiel JJ, Gustafsson JA, Sutherland RL. Frequent loss of estrogen receptor-beta expression in prostate cancer. Cancer Res. 2001 Jul 15; 61(14):5331-5. PMID: 11454669.
        View in: PubMed
      149. Henshall SM, Quinn D, Lee CS, Head DR, Golovsky D, Brenner PC, Delprado W, Stricker PD, Grygiel JJ, Sutherland RL. Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients. Clin Cancer Res. 2001 Mar; 7(3):544-50. PMID: 11297246.
        View in: PubMed
      150. Quinn D. The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2001 Mar 1; 344(9):686; author reply 687-8. PMID: 11229338.
        View in: PubMed
      151. Henshall SM, Quinn D, Lee CS, Head DR, Golovsky D, Brenner PC, Delprado W, Stricker PD, Grygiel JJ, Sutherland RL. Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer. Cancer Res. 2001 Jan 15; 61(2):423-7. PMID: 11212224.
        View in: PubMed
      152. Bishop SJ, Murphy JM, Hicks R, Quinn D, Lewis PJ, Grace M, Jellinek MS. What progress has been made in meeting the needs of seriously maltreated children? The course of 200 cases through the Boston Juvenile Court. Child Abuse Negl. 2000 May; 24(5):599-610. PMID: 10819093.
        View in: PubMed
      153. Quinn D, Henshall SM, Head DR, Golovsky D, Wilson JD, Brenner PC, Turner JJ, Delprado W, Finlayson JF, Stricker PD, Grygiel JJ, Sutherland RL. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Cancer Res. 2000 Mar 15; 60(6):1585-94. PMID: 10749127.
        View in: PubMed
      154. Bova RJ, Quinn D, Nankervis JS, Cole IE, Sheridan BF, Jensen MJ, Morgan GJ, Hughes CJ, Sutherland RL. Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clin Cancer Res. 1999 Oct; 5(10):2810-9. PMID: 10537346.
        View in: PubMed
      155. Ricciardelli C, Quinn D, Raymond WA, McCaul K, Sutherland PD, Stricker PD, Grygiel JJ, Sutherland RL, Marshall VR, Tilley WD, Horsfall DJ. Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer. Cancer Res. 1999 May 15; 59(10):2324-8. PMID: 10344737.
        View in: PubMed
      156. He T, Quinn D, Fu E, Wang YK. Analysis of diagnostic metabolites by capillary electrophoresis-mass spectrometry. J Chromatogr B Biomed Sci Appl. 1999 Apr 30; 727(1-2):43-52. PMID: 10360421.
        View in: PubMed
      157. Veness MJ, Quinn D, Ong CS, Keogh AM, Macdonald PS, Cooper SG, Morgan GW. Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experience. Cancer. 1999 Apr 15; 85(8):1758-64. PMID: 10223570.
        View in: PubMed
      158. Spicer ST, Quinn D, Nyi Nyi NN, Nankivell BJ, Hayes JM, Savdie E. Acute renal impairment after immersion and near-drowning. J Am Soc Nephrol. 1999 Feb; 10(2):382-6. PMID: 10215339.
        View in: PubMed
      159. Templeman C, Quinn D, Hansen R, Moreton T, Baber R. An audit of oestrogen implant hormone replacement therapy. Aust N Z J Obstet Gynaecol. 1998 Nov; 38(4):455-60. PMID: 9890234.
        View in: PubMed
      160. Furger C, Fiddes RJ, Quinn D, Bova RJ, Daly RJ, Sutherland RL. Granulosa cell tumors express erbB4 and are sensitive to the cytotoxic action of heregulin-beta2/PE40. Cancer Res. 1998 May 1; 58(9):1773-8. PMID: 9581810.
        View in: PubMed
      161. Quinn D, Wodak A, Day RO. Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users. Clin Pharmacokinet. 1997 Nov; 33(5):344-400. PMID: 9391747.
        View in: PubMed
      162. Quinn D, Gianlupi A, Broste S. The changing radiographic presentation of bronchogenic carcinoma with reference to cell types. Chest. 1996 Dec; 110(6):1474-9. PMID: 8989064.
        View in: PubMed
      163. Quinn D, Day RO. Drug interactions of clinical importance. An updated guide. Drug Saf. 1995 Jun; 12(6):393-452. PMID: 8527014.
        View in: PubMed
      164. Day RO, Quinn D, Conaghan PG, Tett SE. Adverse drug reactions and their measurement in the rheumatic diseases. J Rheumatol. 1995 May; 22(5):983-8. PMID: 8587095.
        View in: PubMed
      165. Quinn D, Pocock N, Freund J, Kelleher A, Penny R, Brew B. Radionuclide hepatobiliary scanning in patients with AIDS-related sclerosing cholangitis. Clin Nucl Med. 1993 May; 18(5):417-22. PMID: 8508578.
        View in: PubMed
      166. Hales CA, Barkin P, Jung W, Quinn D, Lamborghini D, Burke J. Bronchial artery ligation modifies pulmonary edema after exposure to smoke with acrolein. J Appl Physiol (1985). 1989 Sep; 67(3):1001-6. PMID: 2793693.
        View in: PubMed